Antifibrotische Therapien

Schlüsselwörter

idiopathische pulmonale Fibrose - interstitielle Lungenerkrankung - antifibrotische Therapie - Pirfenidon - Nintedanib

Keywords

idiopathic pulmonary fibrosis - interstitial lung disease - antifibrotic therapy - pirfenidone - nintedanib

• Literatur

• 1 Behr J, Günther A, Ammenwerth W et al. S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose. Pneumologie 2013; 67: 81-111
• 2 Boehringer Ingelheim. EMA accepts marketing authorisation application for nintedanib in IPF. http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/05_june_2014_ipf.html Letzter Zugriff 30.10.2014
• 3 Bundesministerium für Gesundheit. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Pirfenidon. BAnz AT 16.04.2012 B6 2012. https://www.bundesanzeiger.de/ebanzwww/wexsservlet?session.sessionid=6d7c57790663ba34320d44553bc7a82f&page.navid=detailsearchlisttodetailsearchdetail&fts_search_list.selected=b36a0b1b1f85dccc&fts_search_list.destHistoryId=78235 Letzter Zugriff 30.10.2014
• 4 Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242
• 5 European Medicines Agency. Bekanntmachung zu Esbriet® – Pirfenidone. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Conclusion/human/002154/WC500159531.pdf Letzter Zugriff: 30.10.2014
• 6 Fibrogen Inc. Fibrogen announces one-year data supporting the safety and efficacy profile of FG-3019 in patients with idiopathic pulmonary fibrosis. http://www.fibrogen.com/press/release/pr_1411230498 Letzter Zugriff 30.10.2014
• 7 Food and Drug Administration. Bekanntmachung des Pulmonary-Allergy Drugs Advisory Committee. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pulmonaryallergydrugadvisoryadvisorycommittee/ucm208806.pdf
• 8 Intermune Inc. Esbriet® (pirfenidone). www.intermune.com/pirfenidone
• 9 Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The pharmaceuticals and medical devices agency annual report FY 2008. www.pmda.go.jp/english/about/pdf/2008/annual_report_FY2008.pdf
• 10 King TE, Bradford WZ, Castro-Bernardini S et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092
• 11 Ma Z, Pan Y, Huang W et al. Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents. Bioorg Med Chem Lett 2014; 24: 220-223
• 12 Martinez FJ, de Andrade J, Anstrom KJ et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2093-2101
• 13 Noble PW, Albera C, Bradford WZ et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769
• 14 Raghu G, Anstrom KJ, King TE et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977
• 15 Richeldi L, Costabel U, Selman M et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087
• 16 Richeldi L, du Bois RM, Raghu G et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082
• 17 Spagnolo P, Del Giovane C, Luppi F et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; CD003134
• 18 Taniguchi H, Ebina M, Kondoh Y et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829